Cannabis oil is used for a surprisingly wide range of conditions, from chronic nerve pain and treatment-resistant epilepsy to anxiety, muscle spasticity, and appetite loss during cancer care. The strongest clinical evidence supports pharmaceutical-grade cannabidiol (CBD) oil for certain rare seizure disorders, while the evidence for most other uses is promising but still catching up to consumer enthusiasm. The side-effect profile is generally mild at low doses, but higher doses of CBD carry a real risk of liver injury, and THC-containing oils come with their own psychiatric and cognitive concerns.
What “Cannabis Oil” Actually Means
The term cannabis oil gets thrown around loosely, and it can refer to very different products depending on who is selling it and where you live. At the broadest level, any oil extracted from the Cannabis sativa plant qualifies. In practice, what matters is the cannabinoid profile. Some products are rich in THC, the compound that produces a high. Others are dominated by CBD, which is not intoxicating. Many fall somewhere in between.
Commercial CBD oils come in three main forms. Isolate products contain purified CBD and nothing else. Broad-spectrum products retain other minor cannabinoids and terpenes from the plant but have the THC stripped out. Full-spectrum products keep everything, including trace amounts of THC (below 0.3% by dry weight in the United States). A rat study comparing these formats found that full-spectrum CBD oil had higher oral bioavailability than isolate or broad-spectrum versions, with the small amount of THC appearing to boost how much CBD actually reached the bloodstream.1PubMed. Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products Whether that translates to meaningfully different therapeutic effects in humans is still being studied, but it is why many consumers gravitate toward full-spectrum products.
One practical note on how you take the oil: many people hold CBD drops under their tongue, assuming this speeds absorption through the mouth’s lining. A trial in healthy men found that sublingual CBD oil drops and swallowed gelatin capsules produced nearly identical blood levels of CBD, suggesting the oil is mostly swallowed before the mouth can absorb it.2PubMed. Cannabidiol Oil Ingested as Sublingual Drops or Within Gelatin Capsules Shows Similar Pharmacokinetic Profiles in Healthy Males So if you dislike the taste of holding oil under your tongue, capsules may work just as well for CBD specifically.
How Cannabinoids Work in the Body
Your body already runs its own cannabinoid signaling system, called the endocannabinoid system. It relies on two main receptors, CB1 and CB2, which respond to molecules your body makes naturally.3PubMed Central. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System CB1 receptors are concentrated in the brain and nervous system, while CB2 receptors show up more in immune cells and peripheral tissues. THC fits neatly into CB1 receptors, which is why it alters mood, perception, and appetite. CBD, on the other hand, has low affinity for CB1 and CB2 receptors and instead works through a broader set of molecular targets, including serotonin receptors and enzymes that break down your body’s own endocannabinoids.4IBRO Neuroscience Reports. Cannabidiol and the corticoraphe circuit in post-traumatic stress disorder This difference in mechanism is why THC and CBD have such different effects and side-effect profiles, even though they come from the same plant. The endocannabinoid system itself influences pain signaling, inflammation, mood, sleep, and immune function, which helps explain why cannabis oil keeps showing up in research across so many unrelated medical conditions.5Neurotherapeutics. The Endocannabinoid System and its Modulation by Phytocannabinoids
Epilepsy and Seizure Disorders
This is where the evidence is strongest and most clear-cut. Pharmaceutical-grade CBD oil (sold as Epidiolex) is approved for severe, treatment-resistant epilepsy syndromes including Lennox-Gastaut syndrome and Dravet syndrome. A large randomized trial found that patients with Lennox-Gastaut syndrome taking 20 mg/kg/day of CBD experienced about a 42% median reduction in drop seizures, compared with about 17% for placebo.6PubMed. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome Even the lower dose of 10 mg/kg/day outperformed placebo, with a 37% reduction.
Real-world data tells a similar story. In a study of Korean patients with these syndromes, roughly a third of those with Lennox-Gastaut syndrome achieved at least a 50% reduction in seizure frequency at three months, with somewhat lower numbers at six months.7PubMed Central. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea These are patients for whom conventional medications had already failed, so even partial improvement represents a meaningful gain in quality of life. The approval of CBD for epilepsy is one of the few cases where a cannabis-derived product has cleared the full regulatory gauntlet based on rigorous clinical trial data.
Chronic Pain
Pain relief is the most common reason people reach for cannabis oil, particularly for nerve-related pain. A Cochrane review, the gold standard for evidence synthesis, looked at cannabis-based medicines for chronic neuropathic pain and found a modest benefit. About 39% of people using cannabis-based medicines achieved at least 30% pain relief, compared with 33% on placebo. For the higher bar of 50% pain relief, the numbers were 21% versus 17%.8PubMed Central. Cannabis‐based medicines for chronic neuropathic pain in adults That difference is statistically real but clinically small. The review noted that the potential benefits might be outweighed by potential harms for some people.
Those numbers deserve some honest framing. For every 11 people treated, roughly one extra person gets meaningful relief compared with a sugar pill. That is a real effect, but it is not dramatic, and it is for neuropathic pain specifically. Evidence for other pain types, like inflammatory arthritis or back pain, is thinner. Animal research continues to explore combinations, such as CBD-enriched cannabis oil paired with omega-3 fatty acids, which showed promise against nerve pain and motor impairment in a rat model.9PubMed. Full spectrum cannabis oil combined with omega-3 fish oil for neuropathic pain management: a novel therapeutic approach Whether that approach translates to humans remains to be seen.
Anxiety, PTSD, and Mood
CBD has attracted enormous consumer interest as an anxiolytic, and the preclinical evidence is genuinely encouraging. A review of animal and human studies concluded that CBD shows considerable potential for treating generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder, and PTSD.10PubMed Central. Cannabidiol as a Potential Treatment for Anxiety Disorders However, the review was clear about a major limitation: nearly all the positive human evidence involved single-dose experiments, not ongoing treatment. We still have relatively little data on what happens when people use CBD for anxiety over weeks or months.
The PTSD research is particularly interesting mechanistically. CBD appears to act partly through serotonin receptors and partly by boosting your body’s own endocannabinoid levels, which may help modulate fear memories and stress responses.4IBRO Neuroscience Reports. Cannabidiol and the corticoraphe circuit in post-traumatic stress disorder But there is a large gap between understanding the mechanism and having proof from controlled trials in PTSD patients. If you are managing a diagnosed anxiety disorder, CBD oil is not yet a proven substitute for established treatments, though it may eventually earn that role with more research.
Sleep
Sleep is another popular reason people buy cannabis oil, and the picture here is mixed in an interesting way. Preliminary research suggests CBD may help with insomnia, while THC may help you fall asleep faster but could degrade sleep quality over time.11PubMed. Cannabis, Cannabinoids, and Sleep: a Review of the Literature CBD also shows early promise for REM sleep behavior disorder, a condition in which people physically act out their dreams, and for excessive daytime sleepiness. The evidence base is still thin, and most findings come from small studies or clinical observations rather than large randomized trials. If you are using THC-containing oil to help you sleep, be aware that what works in the short term may not serve you well over months of regular use.
Spasticity in Multiple Sclerosis
Nabiximols (brand name Sativex), an oromucosal spray containing roughly equal parts THC and CBD, is approved in several countries outside the United States for spasticity related to multiple sclerosis. A meta-analysis of its clinical trials found it was well tolerated and reduced spasticity.12PubMed. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis A smaller study documented significant improvement on both patient-reported and clinician-measured spasticity scales after nabiximols treatment.13PubMed Central. Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation This is one of the more established medical uses for a cannabis-based product, with regulatory approval in multiple countries to back it up.
Cancer Care and Appetite
Cannabis oil does not treat cancer itself, despite persistent claims on the internet. Where it does have a role is in managing cancer-related symptoms, particularly nausea, pain, and loss of appetite. The appetite evidence, though, is more complicated than many people realize. In studies of advanced cancer patients, appetite increased not just in those taking cannabis-derived products but also in those taking placebos, with cannabis showing no clear advantage over placebo for appetite or weight gain in the cancer setting.14PubMed Central. Opportunities for cannabis in supportive care in cancer The story is different in HIV-related wasting, where three independent controlled trials showed that smoked cannabis and oral THC increased caloric intake and weight gain compared with placebo, particularly in underweight patients. The difference may reflect underlying disease biology, and it highlights why findings from one patient population should not be assumed to apply universally.
Inflammation and Skin Conditions
Cannabis compounds have been studied for inflammatory conditions across several organ systems, including inflammatory bowel diseases like Crohn’s, neurodegenerative conditions with an inflammatory component, and inflammatory skin diseases like atopic dermatitis and psoriasis.15Natural Product Communications. Medical Cannabis for the Treatment of Inflammation Topical CBD products for skin conditions represent a rapidly growing market segment, and there is biological plausibility for their use given the presence of cannabinoid receptors in skin tissue. That said, most of the evidence here comes from preclinical work and small clinical observations rather than large controlled trials. This is an area where consumer spending has far outpaced the science.
Side Effects of CBD Oil
CBD has a reputation as gentle and well tolerated, and at lower doses that reputation is largely earned. But the liver toxicity signal at higher doses is now hard to ignore. A systematic review and meta-analysis of clinical trial data found that CBD use was associated with roughly six times the odds of liver enzyme elevations and about five times the odds of drug-induced liver injury compared with placebo.16PubMed. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis High doses (at or above 1,000 mg/day) and concurrent use of certain antiepileptic drugs were identified as risk factors. Reassuringly, no cases of liver enzyme elevations were reported at doses below 300 mg/day, and no cases of severe liver injury were found in the pooled data.
A 2025 randomized trial in healthy adults put this into sharper focus. Among participants receiving CBD, about 5.6% developed liver enzyme elevations exceeding three times the upper limit of normal within four weeks, while nobody in the placebo group did.17JAMA Internal Medicine. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial Five of the affected participants had elevations above five times normal, accompanied by eosinophilia, a type of immune response. An earlier analysis of a smaller group of healthy volunteers found even higher rates at therapeutic doses of 1,500 mg/day, with nearly a third meeting criteria for drug-induced liver injury.18PubMed Central. Metabolism and liver toxicity of cannabidiol
For context, 1,500 mg/day is the dose used in pharmaceutical epilepsy treatment. Most consumer CBD oils recommend far lower doses, often 25 to 50 mg/day. At those levels, the liver risk appears minimal. But people self-medicating at higher doses, or combining CBD with other liver-metabolized drugs, should be aware of this signal. Routine side effects of CBD at typical consumer doses tend to be milder: drowsiness, diarrhea, and changes in appetite are the most commonly reported.
Side Effects of THC-Containing Oils
THC carries a different side-effect profile. A meta-analysis of controlled studies found that THC produced a large increase in psychiatric symptom severity compared with placebo, including both positive symptoms (like paranoid thoughts and perceptual distortions) and negative symptoms (like apathy and social withdrawal).19PubMed Central. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis These were acute, experimentally administered doses, but they underscore why THC-rich cannabis oil is not benign for everyone, particularly for people with a personal or family history of psychosis. Other common THC side effects include impaired short-term memory, increased heart rate, dry mouth, and motor coordination problems.
There is also the question of dependence. Cannabis use disorder is a recognized condition, and the neurobiological pattern it follows is broadly similar to that of other substances of abuse, with changes in reward circuitry, stress sensitivity, and executive control over time.20SpringerLink / Journal of Neuroimmune Pharmacology. Cannabis Addiction and the Brain: a Review The risk is lower than with alcohol or opioids, but it is not zero, and it rises with heavier, longer-term use.
Drug Interactions
This is an underappreciated risk. Both CBD and THC are processed by the same liver enzymes that metabolize many prescription medications. A systematic review predicted that drug interactions are particularly likely with medications that rely on the CYP2C9 and CYP2C19 enzyme pathways.21PubMed Central. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis Drugs with a narrow therapeutic index, meaning the gap between an effective dose and a dangerous one is small, are the biggest concern. Blood thinners like warfarin, certain anti-seizure medications, and some immunosuppressants fall into this category.
In laboratory studies, CBD was the most potent inhibitor of several CYP enzymes among the cannabinoids tested, with CYP2C9 being inhibited by nearly all cannabinoids at concentrations that could realistically be reached during human use.22PubMed. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization The clinical significance of many of these interactions remains uncertain, but if you take prescription medications, particularly those your doctor monitors with blood tests, talking to your pharmacist or prescriber before adding cannabis oil is not just cautious but genuinely important.23PubMed. Cannabinoids and Cytochrome P450 Interactions
Product Quality Is a Real Problem
One issue that rarely makes it into the marketing materials is how unreliable off-the-shelf cannabis oil products can be. A large study of commercially available CBD products in the United States found that only 42% contained CBD within 10% of what the label claimed. Forty percent had less CBD than advertised, and 18% had substantially more.24PubMed. Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products Beyond label accuracy, there were contamination issues. Lead was detected in 42% of edible CBD products, mercury in 37%, and arsenic in 28%. Phthalates, which are plasticizers that can act as endocrine disruptors, were found in up to 80% of products tested depending on the specific compound.
These findings are not unusual in a market that, in the United States, has no mandatory federal testing or standardized manufacturing requirements for most CBD products. When you buy a cannabis oil from a dispensary in a regulated state, it has typically been tested for potency and contaminants. When you buy one online or in a gas station, you may be getting a well-made product or you may be getting something with the wrong dose and trace heavy metals. Third-party certificates of analysis from independent labs are the closest thing to a quality guarantee available to consumers right now.
Cannabis Oil for Pets
Veterinary use is growing fast, particularly for dogs. A pharmacokinetic study in healthy dogs and cats found that CBD-rich hemp oil given twice daily did not produce concerning changes on blood work in either species, though one cat showed a persistent rise in a liver enzyme for the duration of the trial.25MDPI / Animals. Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats Cats absorbed CBD differently than dogs, reaching lower blood concentrations and showing some adverse reactions during administration like head-shaking and excessive licking. Dog owners primarily seek CBD oil for osteoarthritis pain and anxiety, and the early safety data is cautiously encouraging, though large-scale efficacy trials are still needed. Products marketed for pets are not regulated to the same standard as veterinary pharmaceuticals, so the same label-accuracy and contamination concerns that plague the human market apply here too.
Minor Cannabinoids on the Horizon
CBD and THC dominate the conversation, but the cannabis plant produces over a hundred other cannabinoids, several of which are now attracting research interest. Cannabigerol (CBG) is one of the most studied among these. It is non-intoxicating and has been explored for potential anti-inflammatory, pain-relieving, and even anti-cancer properties in preclinical models, interacting with CB1 and CB2 receptors as well as other signaling pathways.26PubMed Central. Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential CBG-enriched oils are already showing up on consumer shelves, though the human clinical data behind them is essentially nonexistent. The history of cannabis pharmacology suggests the plant still has surprises in store, but for now, CBG and its relatives are best understood as interesting molecules awaiting their turn in clinical trials, not as proven therapies.
Thousands of Years of Use, Decades of Modern Science
It is worth noting that cannabis oil occupies an unusual position in medicine: a substance with thousands of years of documented use whose modern scientific study is still in relative infancy. Written records describing medical cannabis date back to foundational Ayurvedic texts around 800 BCE and to the Chinese pharmacopoeia from the first century BCE, with uses that included inflammation, infection, and seizures.27PubMed. Medical Cannabis: A plurimillennial history of an evergreen The alignment between those ancient uses and the conditions where modern research shows the most promise is striking, if not proof of anything on its own. What decades of prohibition did was create a gap between widespread human experience with the plant and the controlled clinical data needed to know exactly who benefits, at what dose, with what risks. That gap is closing, but it has not yet closed, and the most honest position for now is that cannabis oil has real therapeutic potential in several specific areas, a side-effect profile that deserves more respect than it gets, and a consumer market that is far ahead of the science guiding it.